NephroDI Therapeutics
Manufacturing · Washington, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2200 32nd Ave W, Seattle, Washington, 98...Phone Number
(206) 696-0546Website
www.nephrodi.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About NephroDI Therapeutics
NephroDI Therapeutics is a pharmaceutical company dedicated to addressing concentration disorders of the kidney, specifically focusing on Nephrogenic Diabetes Insipidus (NDI) in children. The company is developing a first-in-class oral treatment for this rare genetic condition, which causes affected children to produce excessive urine and face severe dehydration risks. NephroDI's innovative approach involves a novel series of AMPK as a potential therapy to improve kidney function. Their target clients are pediatric patients suffering from congenital NDI, a condition that significantly impacts their health and quality of life.Explore more
NephroDI Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NephroDI Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at NephroDI Therapeutics
Funding: Get notified immidiatlly once NephroDI Therapeutics has new funding data
Earning: See what the market has to say on NephroDI Therapeutics recently announced quarterly report
Check out if NephroDI Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when NephroDI Therapeutics launches new products
Click to see if NephroDI Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if NephroDI Therapeutics has recently received funding, and reach out quickly before it becomes old news!
NephroDI Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined NephroDI Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to NephroDI Therapeutics
Compare insights from companies similar to NephroDI Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NephroDI Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NephroDI Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NephroDI Therapeutics.
NephroDI Therapeutics financials insights
Gather financial insights about NephroDI Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Unspecified
$1.6M
NephroDI Therapeutics Tech Stack
A closer look at the technologies used by NephroDI Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
New Hire
Executive Move
New Hire
New Hire
Executive Move
NephroDI Therapeutics News & Media
NephroDI Therapeutics' Founder and CMO Jeff M. Sands, M.D. - GlobeNewswire
April 25, 2025, Seattle, WA – NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its Founder and CMO,...NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease
June 20, 2024 Seattle, WA – NephroDI Therapeutics (NephroDI), a near-clinical stage pharmaceutical company focusing on kidney disorders, announces a Series A investment from life sciences VC Sound Bioventures. Together with a previously announced strategic corporate partnership, the capital will be used to advance NDI-5001, a proprietary small molecule AMPK activator that targets the kidney, initially as a potential first-in-class treatment of Congenital Nephrogenic Diabetes Insipidus (NDI). NDISound Bioventures expands portfolio with new investment in US company NephroDI Therapeutics to accelerate development of NDI-5001 for pediatric orphan kidney disease
Stockholm, Sweden and Washington D.C., USA – 20 June 2024 - Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, today announced a new investment in NephroDI Therapeutics, a US-based, near-clinical stage pharmaceutical company focusing on concentration disorders of the kidney. In conjunction with this investment, Bibhash Mukhopadhyay, Managing Partner at Sound Bioventures, will joiNephroDI Therapeutics Enters Agreement to Develop a First-in-Class Treatment for a Genetic, Rare Disease of the Kidneys
SEATTLE--(BUSINESS WIRE)--NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on concentration disorders of the kidney, announces today it has entered an agreement with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies which identifies and supports early-stage opportunities that can change the landscape of treatments for renal disorders and mental illness. MSRD at Otsuka in the U.S. and NephroD
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NephroDI Therapeutics
Sign Up For FreeTo access detailed company insights
NephroDI Therapeutics is a pharmaceutical company dedicated to addressing concentration disorders of the kidney, specifically focusing on Nephrogenic Diabetes Insipidus (NDI) in children. The company is developing a first-in-class oral treatment for this rare genetic condition, which causes affected children to produce excessive urine and face seve... Read More
